The Toxoid Vaccines market is poised for robust expansion, crossing the USD 10 billion mark by the early 2030s. While North America currently leads in revenue, the center of gravity is shifting toward the Asia-Pacific region, led by innovators like Bharat Biotech and Biological E. The